Efficacy of Cpx-351 (liposomal daunorubicin:cytarabine) in patients with secondary acute myeloid leukemia
Latest Information Update: 21 Jul 2020
Price :
$35 *
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 21 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association